SIX DOLLARS!!!!!!

[uvula]

We hit 6.

[sayhey24]

Think what it would be if Mike got insurance coverage without pre-auths.

[ktim]

Think what it will be if Mike progresses the pipeline as planned.

[sayhey24]

Jul 16, 2024 10:26:59 GMT -5 ktim said:

Think what it will be if Mike progresses the pipeline as planned.

IMO, MNKD-101 and 201 are small potatoes if afrezza's three issues were solved; label; SoC; Cost.

Announcing a T2 afrezza/glp1 adder study would also get me excited.  Announcing a study putting a glp1 analog on TS would really get me excited.

[cretin11]

All of the above, please!

[stockwhisperer]

Think what it would be if MC was never here… very likely bankrupt which some certainly hoped would happen. Those days are long gone, thanks - imo, to none other than Mike. Focusing on the now… $6+Carry on.

[prcgorman2]

I think a measured investment in Afrezza is prudent. I think over investing in Afrezza right now would be imprudent. I won't call it throwing good money after bad. Investing in the pipeline for lung illnesses or other non-diabetes treatment has a lot less competition and is more appropriate at this stage in Afrezza's life cycle.

[castlerockchris]

Peds approval will double scripts within 12 months and then we invest the incremental Afrezza profits in additional inhale studies to further improve the growth. Our MNKD team is not a bunch of dolts. If they think they could get the SOC, insurance, label changes done, they will be working on it - they have every incentive in the world to export the lowest hanging fruit to maximize the stock price. My gut tells me MC is take an incremental approach to the future of Afrezza (one small win after another), which given all we have been through with it, is smart. Hopefully in the next 12 to 24 months we will no longer be a one trick pony (I don't count T-DPI as it isn't ours) and our reps will find it easier to get the attention of the right doctors (Hey doc look at what MNKD 101, 201 and afrezza are doing for patients). Nothing begets success like success.

[sayhey24]

Jul 16, 2024 11:22:21 GMT -5 prcgorman2 said:

I think a measured investment in Afrezza is prudent. I think over investing in Afrezza right now would be imprudent. I won't call it throwing good money after bad. Investing in the pipeline for lung illnesses or other non-diabetes treatment has a lot less competition and is more appropriate at this stage in Afrezza's life cycle.

Did you mean Steve Binder?  Without Steve and Martine we were doomed.

Why should we believe Mike can deliver MNKD-101 and 201 when it took 10 years to do the Inhale-3 study and figure out dosing on the label is wrong?  I think all he needed to do was read proboards about 8 years ago when he first came.  8 years later and the label is still wrong and not much progress on the SoC and no insurance without pre-auths.

Why shouldn't we fix the 3 known issues on our FDA approved product which is the greatest advance in diabetes care in over 100 years before we go off on another boon-doggle?  How about we go after some low hanging fruit with gestational diabetes?  My goodness in recent memory we have V-Go and now Pulmatrix.  Its always a shinny new object with Mike.  What can make money for MNKD today is afrezza and once the issues are fixed it can make huge money and Mike can rehire his sales staff and not RIF them this time.

[celo]

Seems to be a little resistance around the 6 level. Eventually it will just look like another stepping stone toward the push upward.

[sayhey24]

Jul 16, 2024 12:17:07 GMT -5 castlerockchris said:

Peds approval will double scripts within 12 months and then we invest the incremental Afrezza profits in additional inhale studies to further improve the growth. Our MNKD team is not a bunch of dolts. If they think they could get the SOC, insurance, label changes done, they will be working on it - they have every incentive in the world to export the lowest hanging fruit to maximize the stock price. My gut tells me MC is take an incremental approach to the future of Afrezza (one small win after another), which given all we have been through with it, is smart. Hopefully in the next 12 to 24 months we will no longer be a one trick pony (I don't count T-DPI as it isn't ours) and our reps will find it easier to get the attention of the right doctors (Hey doc look at what MNKD 101, 201 and afrezza are doing for patients). Nothing begets success like success.

I think the MNKD-101 and 201 are different docs from afrezza and both products are years from approval.

I also think we need big wins for afrezza.  We need the Inhale-3 final results to show superiority.  We need the gestational trial sooner than later and to show superiority.  We need the afrezza to glp1 adder trial started asap and we need the Inhale-2 results to show superiority by a mile.  We need the 1.5 - 2.0 A1c reduction Mike mentioned awhile back.

 I sure hope you are right that they are working on the SOC, insurance, and label changes but its been 10 years so I am really tired of talk.
.

[prcgorman2]

Jul 16, 2024 13:18:49 GMT -5 sayhey24 said:

Jul 16, 2024 11:22:21 GMT -5 prcgorman2 said:

I think a measured investment in Afrezza is prudent. I think over investing in Afrezza right now would be imprudent. I won't call it throwing good money after bad. Investing in the pipeline for lung illnesses or other non-diabetes treatment has a lot less competition and is more appropriate at this stage in Afrezza's life cycle.

Did you mean Steve Binder?  Without Steve and Martine we were doomed.

Why should we believe Mike can deliver MNKD-101 and 201 when it took 10 years to do the Inhale-3 study and figure out dosing on the label is wrong?  I think all he needed to do was read proboards about 8 years ago when he first came.  8 years later and the label is still wrong and not much progress on the SoC and no insurance without pre-auths.

Why shouldn't we fix the 3 known issues on our FDA approved product which is the greatest advance in diabetes care in over 100 years before we go off on another boon-doggle?  How about we go after some low hanging fruit with gestational diabetes?  My goodness in recent memory we have V-Go and now Pulmatrix.  Its always a shinny new object with Mike.  What can make money for MNKD today is afrezza and once the issues are fixed it can make huge money and Mike can rehire his sales staff and not RIF them this time.

I didn't make the remark about MC having saved MannKind from bankruptcy (although I agreed with it).

Love your passion for Afrezza but my opinion is fixing the things you want done is not a trivial exercise, or it would have been taken care of a long time ago.  I believe Dr. David Kendall was an important contributor to the design of the INHALE-1 and INHALE-3 studies, but without money, there wasn't much more he could do for Afrezza.  I assume the interim results of the INHALE-3 study which were presented at ADA in June are a primary reason for the current bull run of MNKD.  I believe the INHALE-1 results next year will be even more impressive.  My thanks to Dr. Kendall and the whole MannKind team.

I think those results and that work is a very good recipe for success with Afrezza without having to spend a lot of money buying off the PBMs.  As agedhippie and others have told you, modifying the SOC is not a trivial exercise because you don't just go do it, you have to have the support of the committee of folks who manage the SOC.  The label is also not easily changed because it requires satisfying the FDA about things they've not been satisfied about and the #1 issue I see is full-scale clinical trial to prove superiority.  Perhaps it will be an outcome of the INHALE-1 pediatric trial, but that is already well underway (although it was delayed by more than a year because of COVID).

So while I love your passion and agree that Afrezza should be more widely prescribed and embraced by the medical community, underwriters, and regulators, I think the course we're on is the right one to address those concerns.

That said, I know you don't agree and will argue and that is your prerogative and these days I want to encourage others with divergent views to share their views because I want humanity to be "kinder and gentler" and besides which I may learn something.  Please try not to run over the same old ground if you can help it though.

[uvula]

You guys are mucking up my thread.

We hit $6.

[ktim]

Jul 16, 2024 12:17:07 GMT -5 castlerockchris said:

Peds approval will double scripts within 12 months and then we invest the incremental Afrezza profits in additional inhale studies to further improve the growth. Our MNKD team is not a bunch of dolts. If they think they could get the SOC, insurance, label changes done, they will be working on it - they have every incentive in the world to export the lowest hanging fruit to maximize the stock price. My gut tells me MC is take an incremental approach to the future of Afrezza (one small win after another), which given all we have been through with it, is smart. Hopefully in the next 12 to 24 months we will no longer be a one trick pony (I don't count T-DPI as it isn't ours) and our reps will find it easier to get the attention of the right doctors (Hey doc look at what MNKD 101, 201 and afrezza are doing for patients). Nothing begets success like success.

I'm curious as to where you came up with doubling of scripts within 12 months after peds approval.  That seems to be at least double what MNKD presented in the one source where they projected contribution of peds separately to existing adult indication. 

Though adding 50% to scripts would be great development, as it seems actual patient increase has been very slow with revenue increase primarily driven by increase in revenue per patient for quite a few years now.

Unless MNKD devotes a LOT of money to larger and longer studies, such as showing improved cardiovascular results, lower expenses from fewer complications, etc., having Afrezza become preferred in ADA SOC (presumably what you mean) or having insurance broadly cover it are unlikely. 

[dh4mizzou]

Wow. I'm surprised we hit $6.00 again in the same day.